# Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT06973330** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- AFP Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SOX regimen combined with Sintilimab and Apatinib

## Key facts

- **NCT ID:** NCT06973330
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973330, "Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06973330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*